Calidi Biotherapeutics Inc.
CLDI
Quantitative and Qualitative Disclosures about Market Risk We are not currently exposed to significant market risk related to changes in interest rates because we do not have any cash equivalents or interest-bearing investments at this time. Our debt typically contains a fixed interest rate or is issued to certain lenders, including related party lenders, with other equity instruments, such as …
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$16M
▲ +10.1% YoY
Op. Margin
–
ROIC
-253.18%
▲ +4.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$16M
▼ -8.1% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$4M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CLDI
Calidi Biotherapeutics (CLDI) in three numbers
Questions about Calidi Biotherapeutics
Is Calidi Biotherapeutics (CLDI) overvalued?
Calidi Biotherapeutics trades at 11.94 times earnings. Intrinsiqq's fair value calculator has no opening value for CLDI, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Calidi Biotherapeutics a high-quality business?
Calidi Biotherapeutics scores 19 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is net debt at -$3M, and its weakest is return on capital at -253.2%. The Quality tab shows every check against its target.
Does Calidi Biotherapeutics (CLDI) pay a dividend?
No. Calidi Biotherapeutics (CLDI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CLDI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CLDI
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.